BD SurePath™ liquid-based Pap Test


The time is right for the BD SurePath™ test.

BD SurePath™ liquid-based Pap test  

“Comparison of the effectiveness of two liquid-based Papanicolaou systems in the handling of adverse limiting factors, such as excessive blood”
BJ Sweeney, Z Haq, JF Happel, B Weinstein, D Schneider
Cancer Cytopathology; February 25, 2006, Vol 108(1), pp.27-31.


BACKGROUND
Excessive blood may compromise gynecologic Papanicolaou (Pap) smears. Liquid-based cytologic techniques have been developed in part to address this problem. In the current study, conditions of excessive blood were simulated to compare the ability of two liquid-based systems, ThinPrep® and SurePath®, to satisfactorily process specimens in the presence of this potentially limiting factor.

METHODS
Equal volumes of washed epithelial cells derived from pooled residues of liquid Pap vials were added to a series of ThinPrep® and SurePath® vials. Increasing volumes of freshly drawn, packed erythrocytes were added to the vials involumes of freshly drawn, packed erythrocytes were added to the vials in progressive amounts from 50 uL or 100 uL up to 3000 uL. The vials were processed on their respective instruments according to U.S. Food and Drug Administration-approved procedures for a total of six test runs. The cellularity of the slides was measured by averaging epithelial cell counts in a total of five 40 fields.

RESULTS
SurePath® preparations were uncompromised by blood until aliquots from 1000 uL to 3000 uL were reached. The ThinPrep® system invariably was overwhelmed by the first 50-uL or 100-uL aliquot of blood, with epithelial cell counts dropping immediately to near zero.

CONCLUSIONS
The cell enrichment process of the SurePath® system capably handled significantly greater amounts of potentially obscuring blood than the membrane filtration method of the ThinPrep® system, which was compromised by as little as 1 drop of packed erythrocytes (1 drop 65 uL).

Sweeney graph

 
 

Clinical News

Independent study on the effect of blood on cellularity of cervical sample.

BD SurePath™ Pap Test Direct to Vial Clinical Study.

Study shows that rinsing sampling devices does not transfer all the sampled cervical cells to the vial for analysis.

*ThinPrep® is a registered trademark of the Cytyc Corporation.

 

Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2014 BD